Evidence map›Paper›PMID 26921317›Full record

ArticleThe Journal of biological chemistry2016

Mutation of Serine 32 to Threonine in Peroxiredoxin 6 Preserves Its Structure and Enzymatic Function but Abolishes Its Trafficking to Lamellar Bodies.

Elena M Sorokina, Chandra Dodia, Suiping Zhou, Jian-Qin Tao, Ling Gao, Tobias Raabe, Sheldon I Feinstein, Aron B Fisher

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Mouse Models of Genetically Altered Peroxiredoxin 6.Antioxidants (Basel, Switzerland) · 2019
    Review
  9. Article
  10. The Role of Peroxiredoxin 6 in Cell Signaling.Antioxidants (Basel, Switzerland) · 2018
    Review
  11. The phospholipase AJournal of lipid research · 2018
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Elena M SorokinaFrom the Institute for Environmental Medicine, Department of Physiology, and.
Chandra DodiaFrom the Institute for Environmental Medicine, Department of Physiology, and.
Suiping ZhouFrom the Institute for Environmental Medicine, Department of Physiology, and.
Jian-Qin TaoFrom the Institute for Environmental Medicine, Department of Physiology, and.
Ling GaoFrom the Institute for Environmental Medicine, Department of Physiology, and.
Tobias RaabePenn Gene Targeting Core and Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Sheldon I FeinsteinFrom the Institute for Environmental Medicine, Department of Physiology, and.
Aron B FisherFrom the Institute for Environmental Medicine, Department of Physiology, and abf@mail.med.upenn.edu.
University of Pennsylvania · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
Role of Peroxiredoxin 6 in the Repair of Peroxidized Cell MembranesR01HL102016 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FISHER, ARON B. · 2010 to 2018
$4.6M
Role of Prdx6 in the activation of NADPH oxidaseR01HL105509 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI FISHER, ARON B. · 2011 to 2015
$2.6M
NHLBI NIH HHS R01 HL102016NHLBI NIH HHS R01 HL105509NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

Peroxiredoxin 6 (Prdx6), a bifunctional protein with phospholipase A2 (aiPLA2) and GSH peroxidase activities, protects lungs from oxidative stress and participates in lung surfactant phospholipid turnover. Prdx6 has been localized to both cytosol and lamellar bodies (LB) in lung epithelium, and its organellar targeting sequence has been identified. We propose that Prdx6 LB targeting facilitates its role in the metabolism of lung surfactant phosphatidylcholine (PC). Ser-32 has been identified as the active site in Prdx6 for aiPLA2 activity, and this activity was abolished by the mutation of serine 32 to alanine (S32A). However, aiPLA2 activity was unaffected by mutation of serine 32 in Prdx6 to threonine (S32T). Prdx6 protein expression and aiPLA2 activity were normal in the whole lung of a "knock-in" mouse model carrying an S32T mutation in the Prdx6 gene but were absent from isolated LB. Analyses by proximity ligation assay in lung sections demonstrated the inability of S32T Prdx6 to bind to the chaperone protein, 14-3-3ϵ, that is required for LB targeting. The content of total phospholipid, PC, and disaturated PC in lung tissue homogenate, bronchoalveolar lavage fluid, and lung LB was increased significantly in Prdx6-S32T mutant lungs, whereas degradation of internalized [(3)H]dipalmitoyl-PC was significantly decreased. Thus, Thr can substitute for Ser for the enzymatic activities of Prdx6 but not for its targeting to LB. These results confirm an important role for LB Prdx6 in the degradation and remodeling of lung surfactant phosphatidylcholine.

Indexed as

Mutation, MissensePeroxiredoxin VI14-3-3 ProteinsAmino Acid SubstitutionAnimalsCell LineHumansMiceMice, TransgenicPhosphatidylcholinesProtein Structure, TertiaryProtein TransportPulmonary SurfactantsRespiratory Mucosa14-3-3 ProteinsPeroxiredoxin VIPhosphatidylcholinesPRDX6 protein, humanPrdx6 protein, mousePulmonary SurfactantsYWHAE protein, humanYwhae protein, mouse14-3-3 proteinlungperoxiredoxinphospholipase Aphospholipid metabolism

Identifiers

PMID26921317
PMCPMC4861491
OpenAlexW2278611165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.